Another study showed that MEG3 in PBMCs was negatively associated with disease activity, lesion joints, and inflammation in RA patients (n = 191), which could be used as a biomarker in monitoring the treatment efficacy of RA (160). The gene discussed is MEG3; the disease is rheumatoid arthritis.